Mapping the Future of Prostate Cancer Treatment: A Vision Led by Michael Krachon
Theragenics’ President, Michael Krachon, was recently featured in a Vision leadership profile highlighting the company’s long-standing commitment to advancing prostate cancer care.
For more than four decades, Theragenics has been a global leader in radioisotope-based therapies, delivering precision LDR brachytherapy solutions—including TheraSeed® Pd-103, AgX100® I-125, and Cesium-131 — used by clinicians worldwide.
In the article, Krachon discusses:
- The urgent need to increase awareness and access to LDR brachytherapy
- How Theragenics’ vertically integrated production model ensures safety, reliability, and quality
- The company’s growing patient advocacy platform, Life After Seeds
- The culture of innovation driving future radioisotope technologies
“At Theragenics, every seed is made for a specific person. This work is deeply personal—and our mission is to improve care for every patient who depends on us.”
Read the full feature to learn more about Theragenics’ vision and the future of prostate cancer treatment.